TORONTO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and FFH.U) announces that, on December 20, 2026, it is redeeming all of its outstanding 4.25% senior notes due December 6, 2027 (the “Notes”) at a redemption price of 100.375% of the principal amount of the Notes, plus accrued and unpaid interest. There is C$650 million principal amount of Notes currently outstanding.

Questions regarding the redemption of the Notes may be directed to Computershare Advantage Trust of Canada, as Canadian Trustee, as follows:

  Computershare Advantage Trust of Canada
88A East Beaver Creek Rd.
Richmond Hill, Ontario L4B 4A8

Fairfax is a holding company which, through its subsidiaries, is primarily engaged in property and casualty insurance and reinsurance and the associated investment management.

For further information contact: John Varnell, Vice President, Corporate Development at (416) 367-4941


Certain statements contained herein may constitute “forward-looking statements” and are made pursuant to the “safe harbour” provisions of applicable Canadian and U.S. securities laws. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Fairfax to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to: our ability to complete acquisitions and other strategic transactions on the terms and timeframes contemplated, and to achieve the anticipated benefits therefrom; a reduction in net earnings if our loss reserves are insufficient; underwriting losses on the risks we insure that are higher than expected; the occurrence of catastrophic events with a frequency or severity exceeding our estimates; changes in market variables, including unfavourable changes in interest rates, foreign exchange rates, equity prices and credit spreads, which could negatively affect our operating results and investment portfolio; the cycles of the insurance market and general economic conditions, which can substantially influence our and our competitors’ premium rates and capacity to write new business; insufficient reserves for asbestos, environmental and other latent claims; exposure to credit risk in the event our reinsurers fail to make payments to us under our reinsurance arrangements; exposure to credit risk in the event our insureds, insurance producers or reinsurance intermediaries fail to remit premiums that are owed to us or failure by our insureds to reimburse us for deductibles that are paid by us on their behalf; our inability to maintain our long term debt ratings, the inability of our subsidiaries to maintain financial or claims paying ability ratings and the impact of a downgrade of such ratings on derivative transactions that we or our subsidiaries have entered into; risks associated with implementing our business strategies; the timing of claims payments being sooner or the receipt of reinsurance recoverables being later than anticipated by us; risks associated with any use we may make of derivative instruments; the failure of any hedging methods we may employ to achieve their desired risk management objective; a decrease in the level of demand for insurance or reinsurance products, or increased competition in the insurance industry; the impact of emerging claim and coverage issues or the failure of any of the loss limitation methods we employ; our inability to access cash of our subsidiaries; an increase in the amount of capital that we and our subsidiaries are required to maintain and our inability to obtain required levels of capital on favourable terms, if at all; the loss of key employees; our inability to obtain reinsurance coverage in sufficient amounts, at reasonable prices or on terms that adequately protect us; the passage of legislation subjecting our businesses to additional adverse requirements, supervision or regulation, including additional tax regulation, in the United States, Bermuda, Canada or other jurisdictions in which we operate; risks associated with applicable laws and regulations relating to sanctions, anti-money laundering and corrupt practices in Canada and in foreign jurisdictions in which we operate; risks associated with government investigations of, and litigation and negative publicity related to, insurance industry practice or any other conduct; risks associated with political and other developments in foreign jurisdictions in which we operate; risks associated with legal or regulatory proceedings or significant litigation; failures or security breaches of our computer and data processing systems; the influence exercisable by our significant shareholder; adverse fluctuations in foreign currency exchange rates; our dependence on independent brokers over whom we exercise little control; financial reporting risks relating to deferred taxes associated with amendments to IAS 12 – Income Taxes; impairment of the carrying value of our goodwill, indefinite-lived intangible assets or investments in associates; our failure to realize deferred income tax assets; risks associated with Canadian or foreign tax laws, or the interpretation thereof; technological or other change that adversely impacts demand, or the premiums payable, for the insurance coverages we offer; disruptions of our information technology systems; assessments and shared market mechanisms that may adversely affect our insurance subsidiaries; risks associated with economic disruptions from global conflicts and the development of other geopolitical events worldwide; and risks associated with tariffs, trade restrictions, or other regulatory measures imposed by domestic or foreign governments that may, directly or indirectly, affect our business. Additional risks and uncertainties are described in our most recently issued Annual Report, which is available at 
www.fairfax.ca and on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov, and in our base shelf prospectus (under “Risk Factors”) filed with the securities regulatory authorities in Canada, which is available on SEDAR+ at www.sedarplus.ca. Fairfax disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — Brainstorm Cell Therapeutics Inc. (OTCQB: BCLI) has released the following notice. The full Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters and the Stipulation and Agreement of Settlement, with its exhibits, are available at https://brainstorm-cell.com/investors/ .

UNITED STATES DISTRICT COURT

SOUTHERN DISTRICT OF NEW YORK

IN RE BRAINSTORM CELL THERAPEUTICS, INC. DERIVATIVE LITIGATION

Lead Case No. 1:24-cv-01095-DEH
SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF STOCKHOLDER DERIVATIVE MATTERS
EXHIBIT D

TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF BRAINSTORM CELL THERAPEUTICS INC. (“BRAINSTORM” OR THE “COMPANY”) COMMON STOCK AS OF NOVEMBER 2, 2026, WHO CONTINUE TO OWN SUCH SHARES (“CURRENT BRAINSTORM STOCKHOLDERS”).

PLEASE READ THIS SUMMARY NOTICE CAREFULLY AND IN ITS ENTIRETY AS YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THE LITIGATION.

YOU ARE HEREBY NOTIFIED that: (i) the above-captioned consolidated stockholder derivative action (the “Derivative Action”); (ii) the action pending in the Delaware Court of Chancery to compel inspection of Brainstorm’s books and records pursuant to 8 Del. C. § 220, styled Shari Roth v. Brainstorm Cell Therapeutics Inc., C.A. No. 2025-1507-DG (Del. Ch.) (the “220 Action”) and the associated inspection demand pursuant to 8 Del. C. § 220 (the “220 Demand”); and (iii) the two litigation demands served on the Board of Directors of Brainstorm (the “Litigation Demands,” and together with the Derivative Action, 220 Action, and 220 Demand, the “Derivative Matters”), are being settled on the terms set forth in the Stipulation and Agreement of Settlement dated November 2, 2026 (the “Stipulation”).1

1 Except as otherwise expressly provided below, all capitalized terms contained herein shall have the same meaning as set forth in the Stipulation.

The Derivative Action is brought derivatively on behalf of nominal defendant Brainstorm and alleges that between February 18, 2020, and September 27, 2023, the Individual Defendants breached their fiduciary duties to the Company by personally making and/or causing the Company to make to the investing public a series of materially false and misleading statements regarding the Company’s business, operations, and prospects. Settling Plaintiff Parties specifically allege that the Individual Defendants willfully or recklessly made and/or caused the Company to make false and misleading statements that failed to disclose, inter alia, that: (i) the U.S. Food and Drug Administration (“FDA”) had already invalidated Brainstorm’s “floor effect” hypothesis, which was based on misleading, post hoc analysis; (ii) certain Chemistry, Manufacturing, and Control issues were not “trivial,” and instead, the FDA informed the Company in a Refuse to File letter that manufacturing was “grossly deficient” and “critical information” was left out; (iii) the FDA had raised other “red flags,” namely there were over three times the number of deaths in the treatment group for the Phase 3 trial of the Company’s amyotrophic lateral sclerosis treatment, NurOwn, compared to placebo and more adverse events which raised serious safety concerns; and (iv) as a result of the foregoing, the Individual Defendants’ statements about Brainstorm’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. The 220 Action was brought against Brainstorm to compel the inspection of Brainstorm’s books and records pursuant to 8 Del. C. § 220 related to substantially the same wrongdoing alleged in the Derivative Action. The Litigation Demands were served on Brainstorm’s Board of Directors to investigate substantially the same wrongdoing as alleged in the Derivative Action. Defendants have denied and continue to deny each and all of the claims and allegations of wrongdoing asserted in the Derivative Matters.

Pursuant to the terms of the Settlement, Brainstorm agrees to implement and maintain certain corporate governance reforms that are outlined in Exhibit A to the Stipulation (the “Reforms”). The Reforms shall be maintained for a minimum of four (4) years. Brainstorm’s Board acknowledges that the Derivative Matters and Settling Plaintiff Parties’ and Settling Plaintiff Parties’ Counsel’s efforts in connection therewith caused the Company to adopt, implement and maintain the Reforms for the agreed upon term, and that the Reforms provide substantial and material benefits to the Company and its stockholders.

After negotiating the material terms of the Settlement, counsel for the Settling Parties negotiated the attorneys’ fees and expenses to be paid to Settling Plaintiff Parties’ Counsel, subject to Court approval. In light of the substantial benefits conferred upon the Company and its stockholders, Defendants’ insurers shall pay to Settling Plaintiff Parties’ Counsel seven hundred twenty-five thousand dollars ($725,000.00) for their attorneys’ fees and expenses (the “Fee and Expense Amount”), subject to Court approval. Defendants also agreed not to object to the request for the Court to approve Service Awards of up to two thousand five hundred dollars ($2,500.00) for each of the six Settling Plaintiff Parties to be paid from the Fee and Expense Amount.

On JANUARY 5, 2027 at 10:00 a.m., a hearing (the “Settlement Hearing”) will be held before the Honorable Dale E. Ho, at the United States District Court for the Southern District of New York, Thurgood Marshall United States Courthouse, 40 Foley Square, New York, NY 10007, in Courtroom 905, for the purpose of determining whether the Settlement should be approved as fair, reasonable, and adequate and whether the Court should approve the agreed-to Fee and Expense Amount and the Service Awards for Settling Plaintiff Parties. Because this is not a class action, except as otherwise provided for in the Stipulation with respect to the Settling Plaintiff Parties, no Current Brainstorm Stockholder has the right to receive any individual compensation as a result of the Settlement.

This Summary Notice provides a condensed overview of certain provisions of the Stipulation and the full Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters (the “Notice”). It is not a complete statement of the events of the Derivative Matters or the terms set forth in the Stipulation. This summary should be read in conjunction with, and is qualified in its entirety by reference to, the text of the Stipulation. For additional information about the claims asserted in the Derivative Matters, and the terms of the proposed Settlement, you may inspect the Stipulation and its exhibits and other papers at the Clerk’s office in the Court at any time during regular business hours. In addition, copies of the Stipulation and its exhibits and the Notice are available on the Investors & Media page of the Company’s website,www.brainstorm-cell.com/investors/.

The Court may, in its discretion, change the date and/or time of the Settlement Hearing without further notice to you. If you intend to attend the Settlement Hearing, please consult the Court’s calendar or the Investors & Media page of the Company’s website,www.brainstorm-cell.com/investors/, for any change in the format, date or time of the Settlement Hearing.

Inquiries about the Derivative Matters or the Settlement may be made to:

Timothy Brown
THE BROWN LAW FIRM, P.C.
1350 Avenue of the Americas, Suite 1200
New York, NY 10019
Telephone: (516) 922-5427
E-mail: tbrown@thebrownlawfirm.net

J. Brandon Walker
BRAGAR EAGEL & SQUIRE, P.C.
1675 Broadway, 14th Floor
New York, NY 10019
Telephone: (212) 308-5858
E-mail: walker@bespc.com

You may enter an appearance before the Court, at your own expense, individually or through counsel of your choice. If you want to object at the Settlement Hearing, you must be a Current Brainstorm Stockholder and you must first comply with the procedures for objecting that are set forth in the Notice. Any objection to any aspect of the Settlement must be filed with the Clerk of the Court and served on Settling Plaintiff Parties’ Counsel and Defendants’ Counsel no later than December 15, 2026 (21 days before the Settlement Hearing), in accordance with the procedures set forth in the Stipulation and the Notice. Any Current Brainstorm Stockholder who fails to object in accordance with such procedures will be bound by the Order and Final Judgment of the Court granting final approval to the Settlement and the releases of claims therein, and shall be deemed to have waived the right to object (including the right to appeal) and forever shall be barred, in this proceeding or in any other proceeding, from raising such objection.

PLEASE DO NOT CALL THE COURT OR DEFENDANTS WITH QUESTIONS ABOUT THE SETTLEMENT.

DATED: November 10, 2026

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK

Contact:
Uri Yablonka, Chief Business Officer
uri@brainstorm-cell.com

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

CALGARY, Alberta, Nov. 20, 2026 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTCQB: GURFF) (the “Company”) announces that it intends to complete a private placement of flow-through units (each, a “Unit”), at a price of $0.70 per Unit, targeting gross proceeds of up to $1.5 million (the “Offering”).

Each Unit will consist of one common share of the Company (a “FT Share”) and one-half of one common share purchase warrant. Each FT Share is intended to qualify as a “flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”). Each whole warrant will entitle its holder to purchase one additional (non-flow-through) common share at $0.85 for two years from the issue date.

The Company anticipates using the proceeds from the sale of the FT Shares to incur Canadian exploration expenses that qualify as “flow-through critical mineral mining expenditures”, as those terms are defined in the Tax Act. The Company intends to renounce qualifying expenditures to the original subscribers in accordance with the Tax Act and the applicable subscription agreements.

The Offering may close in one or more tranches, with final closing anticipated on or before December 11, 2026, subject to applicable regulatory requirements, including those of the Canadian Securities Exchange. All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws.

The Company may pay finder’s fees to eligible finders in connection with the Offering in accordance with applicable securities laws and Canadian Securities Exchange policies.

ABOUT GLOBAL URANIUM CORP.

Global Uranium Corp. focuses on exploring and developing uranium assets primarily in North America. Its portfolio includes the Wing Lake Project in the Mudjatik Domain of northern Saskatchewan, the Astro Project in Saskatchewan’s eastern Athabasca Basin, the Airline Project in Wyoming’s northern Wind River Basin, and additional projects in Wyoming’s Gas Hills and Great Divide districts.

ON BEHALF OF THE BOARD OF DIRECTORS

Ungad Chadda
CEO

587-330-0045
info@globaluranium.com

Forward-looking information

This news release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (collectively, “forward-looking information”), including statements regarding the proposed size, timing, completion and closing of the Offering, the completion of the Offering in one or more tranches, the payment of finder’s fees, the intended qualification of the FT Shares as “flow-through shares” under the Tax Act, the anticipated use of proceeds, the incurrence of eligible Canadian exploration expenses and the renunciation of qualifying expenditures to subscribers. Forward-looking information is based on management’s current expectations, estimates, assumptions and projections, including assumptions regarding investor demand, the receipt of any required regulatory approvals, including acceptance by the Canadian Securities Exchange, the availability of eligible expenditures, the Company’s ability to complete its planned exploration activities and to incur and renounce qualifying expenditures within the required time periods, and the interpretation and application of applicable tax laws. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied, including the risk that the Offering may be delayed, reduced or not completed, that regulatory approvals may not be obtained when anticipated or at all, that the Company may not incur or renounce qualifying expenditures as planned, changes in tax laws or their interpretation, fluctuations in commodity prices and market conditions, the availability of personnel, equipment and financing, exploration and operational risks, and other risks inherent in mineral exploration and development. Accordingly, readers should not place undue reliance on forward-looking information. Although the Company believes that the expectations and assumptions reflected in such information are reasonable, no assurance can be given that they will prove to be correct. The forward-looking information in this news release is provided as of the date hereof, and the Company undertakes no obligation to update or revise it to reflect new events or circumstances, except as required by applicable law.

This release does not constitute an offer to sell or a solicitation of an offer to buy securities in the United States. The securities described herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption.

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

TORONTO, Nov. 20, 2026 (GLOBE NEWSWIRE) — Barrick Mining Corporation (NYSE:B)(TSX:ABX) has received notice of an unsolicited mini-tender offer made by New York Stock and Bond LLC (“NYSB”) to purchase up to 50,000 of Barrick’s common shares at a below-market price of US$26.40 per share. NYSB’s below-market offer price of US$26.40 per share represents a discount of approximately 34.91% to the closing price of Barrick common shares on the New York Stock Exchange on November 6, 2026, the last trading day before the mini-tender offer was commenced. Barrick shareholders who tender their shares in this offer will receive a below-market price.

Barrick recommends shareholders do not tender their shares in response to this unsolicited mini-tender offer because the offer is at a price below the current market price of Barrick’s shares and is subject to numerous conditions. Barrick shareholders who have already tendered their shares may withdraw their shares no more than 14 days after the date of delivery of the shareholder’s acceptance form to the depositary for this offer, in accordance with NYSB’s offer documentation. The offer is currently scheduled to expire at 5:00 p.m., Eastern time, on November 8, 2027, unless it is extended or earlier revoked by NYSB.

Barrick does not endorse NYSB’s unsolicited offer and is not in any way affiliated or associated with NYSB, its offer, or the offer documentation.

Mini-tender offers are designed to avoid investor protections such as disclosure and procedural requirements applicable to most take-over bids and tender offers under Canadian and U.S. securities laws. Both Canadian Securities Administrators (CSA) and the U.S. Securities and Exchange Commission (SEC) recommend that investors exercise caution with mini-tender offers and have expressed serious concerns about mini-tender offers, including the possibility that investors might tender to such offers without understanding the offer price relative to the actual market price of their securities.

The SEC has issued “Tips for Investors” regarding mini-tender offers, noting that some bidders, in making the offers at below-market prices, are “hoping that they will catch investors off guard if the investors do not compare the offer price to the current market price.” The SEC’s advisory may be found on the SEC website at http://www.sec.gov/investor/pubs/minitend.htm.

The CSA’s long-standing guidance on mini-tenders can be found on the Ontario Securities Commission website at www.osc.gov.on.ca/en/SecuritiesLaw_csa_19991210_61-301.jsp.

Brokers, dealers, and other market participants are encouraged to exercise caution and review the letter regarding broker-dealer mini-tender offer dissemination and disclosures on the SEC website at www.sec.gov/divisions/marketreg/minitenders/sia072401.htm.

Barrick shareholders are urged to obtain current market quotations for their shares, consult with their broker or financial advisor, and exercise caution with respect to NYSB’s unsolicited offer.

Barrick requests that a copy of this news release be included in any distribution to Barrick shareholders of materials relating to NYSB’s mini-tender offer for Barrick common shares.

Investor Relations Contact: investor@barrick.com
Media Contact: media@barrick.com

Vancouver, BC, Nov. 20, 2026 (GLOBE NEWSWIRE) — Skyharbour Resources Ltd. (TSX-V: SYH) (OTCQX: SYHBF) (Frankfurt: SC1P) (“Skyharbour” or the “Company”) has engaged Connect 4 Marketing Ltd. (“Connect 4”) to provide digital marketing services designed to increase investor awareness of the Company over a 12-month term.

The Company has entered into a digital marketing services agreement with Connect 4 effective November 20th, 2026 (the “Connect 4 Agreement”). Connect 4 is a company incorporated under the laws of Quebec with an address at 702-5505 Boulevard Du Quartier, Brossard, Quebec, J4Z 0R9. The principal contact for Connect 4 is Louis-Carlos Vargas-Rocheleau, Founder (email: carlos@connect4marketing.ca.

Under the Connect 4 Agreement, Connect 4 will set up the required advertising accounts and channels, prepare influencer scripts and newsletters, build interactive landing pages to host advertising traffic, prepare Google Ads and native advertising descriptions, headlines and graphics, and manage influencer engagements. All materials prepared by Connect 4 will be reviewed and approved by the Company prior to publication.

The fee represents the total consideration and total cost payable by the Company to Connect 4 for the services, and no additional fees, expenses or third-party costs are payable by the Company under the Connect 4 Agreement; any expansion of the scope of the services would require the written agreement of both parties. The fee has been funded from the Company’s working capital.

The Connect 4 Agreement has a term of 12 months commencing November 20th, 2026, and may be extended by mutual agreement of the parties, subject to acceptance by the TSX Venture Exchange. In consideration for the services, the Company will pay Connect 4 total cash consideration of USD $150,000 plus GST payable upon execution of the Connect 4 Agreement. The Company will not issue any securities to Connect 4 (or its directors, officers, or affiliates) as compensation for its services. To the Company’s knowledge, Connect 4 and its founder are at arm’s length to the Company, and neither Connect 4 nor its founder (nor any of Connect 4’s directors, officers, employees or shareholders) has any interest, direct or indirect, in the Company or its securities, or any right or intent to acquire such an interest. The Connect 4 Agreement is subject to the approval of the TSX Venture Exchange.

About Skyharbour Resources Ltd.:

Skyharbour holds an extensive portfolio of uranium exploration projects in Canada’s Athabasca Basin and is well positioned to benefit from improving uranium market fundamentals with interest in forty-nine projects covering over 736,000 hectares (1.8M acres) of land. Skyharbour owns a 100% interest in the Moore Uranium Project, which is located 15 kilometres east of Denison’s Wheeler River project and 39 kilometres south of Cameco’s McArthur River uranium mine. Moore is an advanced-stage uranium exploration property with high-grade uranium mineralization at the Maverick Zones. Adjacent to Moore, Skyharbour is advancing several uranium properties within the broader Russell Lake project area with its joint venture partner and large strategic shareholder Denison Mines. Collectively these co-flagship projects host multiple zones of high-grade uranium mineralization across a highly prospective land package with significant exploration upside, and the Company is actively working on these assets through exploration and drilling programs.

Skyharbour now has joint ventures with industry-leaders Denison Mines and Orano Canada Inc. at the Russell Lake properties and the Preston project, respectively. The Company also has several active earn-in option partners, including CSE-listed Nexus Uranium Corp. at the Mann Lake Uranium Project; TSX-V listed North Shore Uranium at the Falcon Project; UraEx Resources at the South Dufferin and Bolt Projects; Future Fuels at the Highway Project; CSE-listed Mustang Energy at the 914W Project; CSE-listed Purecore Metals at the Yurchison Project, and TSX-V listed Terra Clean Energy at the South Falcon East Project. In aggregate, Skyharbour has now signed earn-in option agreements with partners that total to potentially over $79 million in partner-funded exploration expenditures and over $52 million in cash and share payments coming into Skyharbour, assuming that these partner companies complete the earn-ins at their respective projects.

Skyharbour’s goal is to maximize shareholder value through new mineral discoveries, committed long-term partnerships, and the advancement of exploration projects in geopolitically favourable jurisdictions.

Skyharbour’s Uranium Project Map in the Athabasca Basin:
https://www.skyharbourltd.com/_resources/news/SKY_SaskProject_Locator_2026-09-29_v1.jpg

To find out more about Skyharbour Resources Ltd. (TSX-V: SYH) visit the Company’s website at www.skyharbourltd.com.

SKYHARBOUR RESOURCES LTD.

“Jordan Trimble”
                                                                               
Jordan Trimble
President and CEO

For further information contact myself or:

Nicholas Coltura
Corporate Communications and Development Manager
Skyharbour Resources Ltd.
Telephone: 604-558-5847
Toll Free: 800-567-8181
Facsimile: 604-687-3119
Email: info@skyharbourltd.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Forward-Looking Information:

This news release contains “forward‐looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, the anticipated services, timing and results of the marketing program described herein, receipt of TSX Venture Exchange approval, completing ongoing and planned work on its projects, other statements relating to the technical, financial and business prospects of the Company, its projects and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of uranium, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration results, risks related to the inherent uncertainty of exploration and cost estimates and the potential for unexpected costs and expenses, and those filed under the Company’s profile on SEDAR+ at www.sedarplus.ca. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather or climate conditions, failure to obtain or maintain all necessary government permits, approvals and authorizations, failure to obtain or maintain community acceptance (including First Nations), decrease in the price of uranium and other metals, increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.

               

  • Business combination closed on November 20, 2026; Melar renamed Everli Global Holdings, Inc.
  • Class A common stock and warrants expected to begin trading on the Nasdaq Global Market on Monday, November 23, 2026 under “EVRL” and “EVRLW”
  • Melar units, Class A ordinary shares and warrants to cease trading under “MACIU,” “MACI” and “MACIW” at the close of market today, November 20, 2026

NEW YORK, Nov. 20, 2026 (GLOBE NEWSWIRE) — Melar Acquisition Corp. I (Nasdaq: MACI) (“Melar”) and Everli Global Inc. (“Everli”), the multi-retailer online grocery marketplace that brings Italy’s favorite supermarkets to customers’ phones and front doors, today announced the completion of their previously announced business combination. The transaction closed today, November 20, 2026.

In connection with the closing, Melar changed its name to Everli Global Holdings, Inc. (the “Company”). The Nasdaq Stock Market LLC (“Nasdaq”) has approved the listing of the Company’s Class A common stock and warrants on the Nasdaq Global Market, where they are expected to begin trading on Monday, November 23, 2026, under the ticker symbols “EVRL” and “EVRLW,” respectively. Melar’s units, Class A ordinary shares and warrants will cease trading under “MACIU,” “MACI” and “MACIW,” respectively, at the close of market today. Outstanding units will be automatically separated into their component Class A common stock and warrants of the Company, and no units will trade on Nasdaq following the closing.

Additional details regarding the closing will be included in a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission (“SEC”).

About Everli

Everli is a leading e-grocery marketplace and delivery platform in Italy. Founded in 2014, Everli connects consumers with their preferred grocery retailers through its online platform and a network of over one thousand weekly active independent shoppers who shop and deliver each order end to end, having served millions of Italian households. Everli’s asset-light model gives retailers a fully outsourced e-commerce channel built on their existing store footprint. For more information, visit www.everli.com.

About Melar Acquisition Corp. I

Prior to the closing of the business combination, Melar (Nasdaq: MACI) was a special purpose acquisition company sponsored by Melar Acquisition Sponsor I LLC and incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

No Offer or Solicitation

This press release is not an offer to sell or a solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. federal securities laws, including statements regarding the expected commencement of trading of the Company’s securities on Nasdaq. Actual results may differ materially from those expressed or implied by these statements due to, among other things, the ability to realize the anticipated benefits of the business combination, the inability to maintain the listing of the Company’s securities on Nasdaq, and the other risks described in the “Risk Factors” section of the Registration Statement and other documents filed by Melar and Everli with the SEC. You should not place undue reliance on forward-looking statements, which speak only as of the date made. Neither Melar nor Everli undertakes any obligation to update them, except as required by law. [Counsel to conform to the full legend used in the listing release.]

Media and Investor Relations:
Tony Sklar
Chief Strategy Officer and Head of Investor Relations
Tel: (347) 588-4226
ir@everli.com
ir.everli.com

ST. LOUIS, Nov. 20, 2026 (GLOBE NEWSWIRE) — The Marketing Alliance, Inc. (OTC: MAAL) (“TMA” or the “Company”), announced today the Company’s Board of Directors has authorized a share repurchase program to repurchase up to 800,000 shares of the Company’s issued and outstanding common stock, effective immediately and concluding March 31, 2027.

Timothy Klusas, the Company’s President and Chief Executive Officer, stated, “The Board continues to believe that share repurchases are a superior way to reward shareholders. In the past, the Board felt its policy of paying dividends was not adequately reflected in the stock price.”

Repurchases under the program may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Securities Exchange Act of 1934, as amended. The timing, number and purchase price of shares repurchased under the program, if any, will be determined by management in its discretion and will depend on a number of factors, including the market price of the shares as a percentage of tangible book value, general market and economic conditions, applicable legal requirements and other conditions, and there is no assurance that the Company will purchase any shares under the program.

The repurchase program may be suspended, terminated or modified at any time for any reason, including market conditions, the cost of repurchasing shares, the availability of alternative investment opportunities, liquidity, and other factors deemed appropriate. These factors may also affect the timing and amount of share repurchases. The repurchase program does not obligate the Company to purchase any number of shares.

About The Marketing Alliance, Inc.

Headquartered in St. Louis, MO, TMA provides support to independent insurance brokerage agencies, with a goal of integrating insurance and “insuretech” engagement platforms to provide members value-added services on a more efficient basis than they can achieve individually.

Investor information can be accessed through the shareholder section of TMA’s website at: 
http://www.themarketingalliance.com/shareholder-information.

TMA’s common stock is quoted on the OTC Markets (http://www.otcmarkets.com) under the symbol “MAAL”.

Forward Looking Statement
This press release contains forward-looking statements including, among other things, statements regarding our intended share repurchases and expected shareholder benefits. Any forward-looking statements contained in this press release represent our estimates, expectations or intentions only as of the date hereof, or as of such earlier dates as are indicated, and should not be relied upon as representing our views as of any subsequent date. These statements involve a number of risks, assumptions and uncertainties. If the risks materialize, assumptions prove incorrect, or we experience unexpected changes in circumstances, actual results could differ materially from the results implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, our future financial performance, results of operations or other operational results or metrics, expectations of the economic environment, material adverse changes in economic conditions and the other risks contained in our other public disclosures discussing our business and financial condition and results. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.

Contact:    
The Marketing Alliance, Inc. -OR- The Equity Group Inc.
Timothy M. Klusas, President   Jeremy Hellman, Vice President
(314) 275-8713   (212) 836-9626
tklusas@themarketingalliance.com
www.TheMarketingAllianceinc.com
  jhellman@equityny.com

ROCKVILLE, Md., Nov. 20, 2026 (GLOBE NEWSWIRE) — Theriva™ Biologics, Inc. (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, announced today a reverse stock split of its authorized and issued and outstanding common stock, par value $0.001 per share, at a ratio of one (1) share of common stock for every thirty (30) shares of common stock, effective as of 11:59 p.m. (Eastern Time) on December 1, 2026 (the “Effective Date”).

The Company’s common stock will begin trading on a split-adjusted basis when the market opens on December 2, 2026. The reverse stock split was authorized by the Company’s Board of Directors on November 13, 2026. Pursuant to the laws of the State of Nevada, the Company’s state of incorporation, the Company’s Board of Directors has the authority to effect a reverse stock split without shareholder approval if the number of authorized shares of common stock and the number of outstanding shares of common stock are proportionally reduced. The Company will file a certificate of change to its articles of incorporation, as amended, with the Secretary of State of Nevada to effect the reverse stock split. The Company’s common stock will continue to trade on the NYSE American under the stock ticker “TOVX” but will trade under the new CUSIP number 87164U607.

As a result of the reverse split, each thirty (30) pre-split shares of common stock outstanding will automatically combine into one (1) new share of common stock without any action on the part of the holders, and the number of outstanding common shares will be reduced from 45,892,668 shares to approximately 1,529,756 shares without taking into account fractional shares. The number of authorized shares of common stock will be proportionally reduced from 350,000,000 shares to 11,666,666 shares.

The reverse stock split is being effected to ensure that the Company can meet the per share price requirements of the NYSE American, the Company’s current listing exchange.

No fractional shares will be issued as a result of the reverse stock split. Stockholders who otherwise would be entitled to a fractional share because they hold a number of shares not evenly divisible by the one (1) for thirty (30) reverse split ratio will automatically be entitled to receive an additional fractional share of the Company’s common stock to round up to the next whole share.

Proportionate adjustments will also be made to the number of shares of common stock issuable upon exercise of, and the exercise price of, the Company’s outstanding warrants and stock options, and to the number of shares of common stock reserved for issuance under the Company’s equity incentive plans.

The Company’s transfer agent, Equiniti Trust Company, which is also acting as the exchange agent for the reverse split, will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take action to effect the exchange of their shares.

About Theriva™ Biologics, Inc.

Theriva™ Biologics (NYSE American: TOVX) is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company’s subsidiary Theriva Biologics, S.L., has been developing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and intratumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. The Company’s lead clinical-stage candidate is VCN-01 (zabilugene almadenorepvec), an oncolytic adenovirus designed to replicate selectively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. For more information, please visit Theriva™ Biologics’ website at www.therivabio.com.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases forward-looking statements can be identified by terminology such as “may,” “should,” “potential,” “continue,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” and similar expressions, and include statements regarding our planned reverse stock split, including its expected effective date and the expected commencement of trading on a split-adjusted basis. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the reverse stock split having the desired effect; the Company’s ability to maintain compliance with the continued listing standards of the NYSE American; the Company’s ability to raise capital and/or enter into one or more strategic alternatives, that may include a business combination, merger or reverse merger; the Company’s ability to obtain development funding and/or partnerships; the Company’s ability to receive any milestone or royalty payments from Biossil; the Company’s commencement of planned clinical trials, which remains subject to sufficient financing; the Company’s ability to finalize protocols for future clinical trials evaluating VCN-01; results of future trials supporting further clinical development of VCN-01 and supporting the benefits of more frequent repeated dosing of VCN-01; the Company’s ability to reach clinical milestones when anticipated, including the ability to continue to enroll patients as planned; generating clinical data that establishes VCN-01 may improve patient outcomes in cancer patients; the ability to obtain regulatory approval for commercialization of product candidates or to comply with ongoing regulatory requirements, including approval of VCN-01 to treat cancer patients; regulatory limitations relating to the Company’s ability to promote or commercialize its product candidates for the specific indications; acceptance of the Company’s product candidates in the marketplace; the successful development, marketing or sale of the Company’s products; developments by competitors that render such products obsolete or non-competitive; the Company’s ability to maintain license agreements; the continued maintenance and growth of the Company’s patent estate; the ability to continue to remain well financed; and other factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, including subsequent periodic reports on Forms 10-Q and current reports on Form 8-K. The information in this release is provided only as of the date of this release, and Theriva Biologics undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.

For further information, please contact:

Investor Relations:
Kevin Gardner
LifeSci Advisors, LLC
kgardner@lifesciadvisors.com

Abivax Statement on Short Seller Report

PARIS, France – November 20, 2026 – 10:30 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax,” the “Company,” “we” or “our”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today issued a statement regarding a report published by Scorpion Capital on November 20, 2026.

We are reviewing the Scorpion Capital report in detail and anticipate providing further updates regarding this matter. Based on Abivax’s current review, it is clear that the report contains numerous factually inaccurate and misleading statements, assumptions, and conclusions, including those based on studies commissioned and funded by Scorpion Capital itself. We firmly stand behind the integrity of our clinical development program, including the results of our Phase 3 ABTECT trials and the strength of the clinical data generated to date, which will support Abivax’s U.S. FDA NDA filing by the end of the year.

Notably, Scorpion Capital explicitly disclosed its short position in Abivax and its intention to begin covering a substantial portion of that position upon publication of its report, underscoring its direct financial interest in a decline in our share price. These direct financial incentives provide important context for evaluating the report.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:
Patrick Malloy
SVP, Investor Relations
Abivax SA
patrick.malloy@abivax.com
+1 847 987 4878

Media Contacts:
LifeSci Communications
Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com

Longacre Square Partners
Abivax@longacresquare.com

Attachment

Oatly Confirms Commencement of Tender Offer by Verlinvest

The Disinterested Directors of the Oatly Board are Evaluating the Tender Offer and Urge Securityholders Not to Take Action at This Time

MALMÖ, Sweden, November 20, 2026 – Oatly Group AB (publ) (Nasdaq: OTLY), the world’s original and largest oat drink company (“Oatly”), today confirmed that Verlinvest S.A. (“Verlinvest”) has commenced a tender offer to acquire all of the outstanding (i) ordinary shares of Oatly (“Ordinary Shares”) for $0.2065 per Ordinary Share in cash and (ii) American depositary shares (“ADSs”) of Oatly, each representing twenty Ordinary Shares, for $4.13 per ADS in cash. Verlinvest stated in its Schedule TO that the tender offer is technical in nature and is being made solely to comply with Swedish law requirements in connection with its proposed buyout of China Resources’ indirect interest in Oatly Ordinary Shares and convertible notes held by their joint venture.

Consistent with their fiduciary duties, the disinterested directors of the Oatly board, being the directors other than those affiliated with Verlinvest and China Resources, in consultation with Oatly’s legal advisors, will carefully review and evaluate Verlinvest’s tender offer to determine the course of action that they believe is in the best interests of Oatly and its securityholders.

The disinterested directors of the Oatly board will issue their formal recommendation to Oatly securityholders regarding Verlinvest’s tender offer within ten business days of commencement of the tender offer (by December 4, 2026) by filing a Solicitation/Recommendation Statement on Schedule 14D-9 with the U.S. Securities and Exchange Commission (the “SEC”).

Oatly securityholders are urged not to take any action with respect to the tender offer until the disinterested directors of the Oatly board have reviewed and evaluated the tender offer and issued their recommendation.

White & Case LLP is serving as legal advisor to Oatly.

Important Information and Where to Find It
Verlinvest has commenced a tender offer (the “Tender Offer”) for all of the outstanding (i) Ordinary Shares of Oatly and (ii) ADSs of Oatly pursuant to a Tender Offer Statement on Schedule TO, including an Offer to Purchase, ADS Letter of Transmittal, Acceptance Form for Shares and certain other tender offer documents, that was filed with the SEC on November 20, 2026.

Oatly will file a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the Tender Offer with the SEC within ten business days of November 20, 2026.

This communication is neither a recommendation, an offer to purchase, nor a solicitation of an offer to sell any securities of Oatly. There shall not be any sale of Oatly securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Oatly urges holders of its Ordinary Shares and ADSs to carefully review the Solicitation/Recommendation Statement on Schedule 14D-9, including its exhibits, in their entirety when they become available as they will contain important information that Oatly securityholders should consider before making any decision with respect to the Tender Offer.

You may obtain a free copy of the Solicitation/Recommendation Statement on Schedule 14D-9, including its exhibits, after they have been filed with the SEC on the SEC’s website at www.sec.gov. You may also obtain a free copy of the Solicitation/Recommendation Statement on Schedule 14D-9, including its exhibits, after they have been filed with the SEC, on our website investors.oatly.com.

You should read the Schedule 14D-9, including its exhibits, once filed with the SEC carefully before making any decision with respect to the Tender Offer.

Forward-Looking Statements
This communication may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any express or implied statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements, including, without limitation, statements regarding our financial outlook for 2026, profitability improvement, profitable growth in 2026, long-term growth strategy, expected capital expenditures, anticipated returns on our investments, anticipated supply chain performance, anticipated impact of our improvement plans, anticipated impact of our decision to discontinue construction of certain production facilities, plans to achieve profitable growth and anticipated cost savings and efficiencies as well as statements that include the words “expect”, “intend”, “plan”, “believe”, “project”, “forecast”, “estimate”, “may”, “should”, “anticipate”, “will”, “aim”, “potential”, “continue”, “is/are likely to” and similar statements of a future or forward-looking nature. Forward-looking statements are neither promises nor guarantees, but involve known and unknown risks and uncertainties that could cause actual results to differ materially from those projected, including, without limitation: we have a history of losses, and we may be unable to achieve or sustain profitability, including due to elevated inflation and increased costs for transportation, energy, and materials; our future business, financial condition and results of operations may be adversely affected by reduced or limited availability of oats and other raw materials and ingredients, which meet our quality standards, that our limited number of suppliers are able to sell to us; a failure to obtain necessary capital when needed on acceptable terms, or at all, may force us to delay, limit, reduce or terminate our product manufacturing and development and other operations; the primary components of all our products are manufactured in our production facilities, and damage or disruption at these facilities has in the past harmed, and may in the future harm, our business; our brand or reputation may be harmed due to real or perceived quality, food safety, nutrition or sustainability issues with our products, which could have an adverse effect on our business, reputation, financial condition and results of operations; food safety and food-borne illness incidents or other safety concerns have led to product recalls, and may materially adversely affect our business, financial condition and results of operations by exposing us to lawsuits or regulatory enforcement actions in the future, increasing our operating costs and reducing demand for our product offerings; failure by our suppliers of raw materials or co-manufacturers to comply with food safety, environmental or other laws and regulations, or with the specifications and requirements of our products, may disrupt our supply of products and adversely affect our business; we may not be able to compete successfully in our highly competitive markets; consolidation of customers, the loss of a significant customer or the decrease of sales from a significant customer, could negatively impact our sales and profitability; sales of our oatmilk varieties contribute a significant portion of our revenue and a reduction in such sales would have an adverse effect on our business, financial condition and results of operations; we continue to pursue largely an asset-light business model blending a heavy reliance on our co-manufacturing partners in addition to in-house capacity expansions where appropriate; our strategic partnerships with our co-manufacturers may not be successful, which could adversely affect our operations and manufacturing strategy; failure by our logistics providers to deliver our products on time, or at all, could result in lost sales; we may not successfully ramp up operations at any of our or our co-manufacturing partners’ facilities, or these facilities may not operate in accordance with our expectations; if we fail to effectively expand our processing, manufacturing and production capacity through existing facilities or acceptable co-manufacturing partners as we continue to grow and scale our business to a steady operating level, our business, financial condition, results of operations and our brand reputation could be harmed; if we fail to develop and maintain our brand, our business could suffer; failure to develop or introduce new products or successfully improve existing products may adversely affect our ability to continue to grow; if we fail to cost-effectively acquire new customers and consumers or retain our existing customers and consumers, or if we fail to derive revenue from our existing customers consistent with our historical performance, our business could be materially adversely affected; consumer preferences for our products are difficult to predict and may change, and, if we are unable to respond quickly to new trends, our business may be adversely affected; if we fail to manage our future growth effectively, including maintenance of our workforce, our business, financial condition and results of operations could be materially adversely affected; we have recognized impairment charges for long-lived assets and other exit costs in connection with our production facilities, and we may need to recognize further costs in the future, which could adversely impact our business, financial condition and results of operations; we are subject to risks related to sustainability (including environmental, climate change and broader corporate social responsibility matters), which may materially adversely affect our business as a result of lawsuits, regulatory investigations and enforcement actions, complaints concerning our disclosures, impacts on our operations and supply chain (particularly in connection with the physical impacts of climate change), and impacts on our brand and reputation; we rely on information technology systems and any inadequacy, failure or interruption of, or cybersecurity incidents affecting, those systems may harm our reputation and ability to effectively operate our business; a cybersecurity incident or other technology disruptions could negatively impact our business and our relationships with customers; to remain competitive, we believe we will need to adopt artificial intelligence and other machine learning technologies; our customer agreements do not contain long-term commitments and do not require our customers to continue purchasing products from us, and this may negatively impact our business or financial condition; we may face difficulties as we expand our operations into countries in which we have no prior operating experience; the strategic review of our Greater China operations may not be timely or successful; our operations in China could expose us to substantial business, regulatory, political, financial and economic risks; the international nature of our business subjects us to additional global economic and geopolitical risks; if we fail to comply with trade compliance and economic sanctions laws and regulations of the United States (the “U.S.”), the EU and other applicable international jurisdictions, it could materially adversely affect our reputation and results of operations; some of our debt agreements contain a floating interest rate component and as a result, an increase in market interest rates will increase our future interest payments under such agreements; our international operations expose us to the risk of fluctuations in currency exchange rates; we maintain cash and cash equivalents at financial institutions, often in amounts exceeding insured limits, and the failure of one or more of these institutions could result in a loss of deposits and adversely affect our liquidity or ability to raise capital; packaging costs are volatile and may rise significantly, which may negatively impact the profitability of our business; fluctuations in our results of operations may impact, and may have a disproportionate effect on, our overall financial condition and results of operations; litigation or legal proceedings, or the threat of litigation or legal proceedings, could expose us to significant liabilities or costs and have a negative impact on our reputation or business; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate, and even if the market in which we compete achieves the forecasted growth, our business could fail to grow at similar rates, if at all; failure to retain our senior management or to attract, train and retain qualified employees may adversely affect our operations or our ability to grow successfully; if we cannot maintain our company culture or focus on our mission as we grow, our success and our business and competitive position may be harmed; our insurance may not provide adequate levels of coverage against claims or we may be unable to find insurance with sufficient coverage at a reasonable cost; disruptions in the worldwide economy may adversely affect our business, financial condition and results of operations; our business is affected by macroeconomic conditions, including international tariffs and trade wars, rising inflation, interest rates and supply chain constraints; we are subject to risks inherent to organizations with international operations, which could harm our business, and global conflicts, including the ongoing conflict in the Middle East; legal claims, government investigations or other regulatory enforcement actions could subject us to civil and criminal penalties; our operations are subject to U.S., EU, Chinese and other laws and regulations, and there is no assurance that we will be in compliance with all applicable laws and regulations; changes in existing laws or regulations, or the adoption of new laws or regulations, may increase our costs and otherwise adversely affect our business, financial condition and results of operations; we are subject to stringent environmental regulation and potentially subject to environmental litigation, proceedings and investigations; we may not be able to protect, enforce or defend our intellectual property and other proprietary rights adequately, which may impact our commercial success; we have incurred substantial indebtedness that may decrease our business flexibility, decrease our access to capital, and/or increase our future borrowing costs; risks relating to the Tender Offer, including uncertainty surrounding how many of Oatly’s securityholders will tender their Ordinary Shares and ADSs in the Tender Offer, the effect the Tender Offer may have on the trading price of Oatly’s ADSs, and the response of Oatly’s business partners to the Tender Offer; and the other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on March 13, 2026, and our other filings with the SEC as such factors may be updated from time to time. Any forward-looking statements contained in this press release speak only as of the date hereof, and accordingly, undue reliance should not be placed on such statements. Oatly disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, whether as a result of new information, future events or otherwise, other than to the extent required by applicable law.

For further information:

Contact person
John Baumgartner, CFA, Vice President, Investor Relations
E-mail: investors@oatly.com, press@oatly.com

This information is information that Oatly Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 16:30 ET on November 20, 2026.

Attachment

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.